World Health Organization site
Skip Navigation Links
Home
Advanced Search
List ByExpand List By
Search Tips
UTNExpand UTN
ICTRP websiteExpand ICTRP website
Contact us
                   135 records for 29 trials found!
Trials are sometimes recorded in more than one registry. These records can refer to each other using the 'Secondary ID' field. The search portal uses these Secondary IDs to group records about the same trial together in the search results.
Each group of records referring to a trial is displayed in table that is seen by pressing the + symbol. The record with the earliest date of registration is always shown first.
 
 
 
 
  Showrecords per page     

1 2 3
Recruitment statusMain ID Public TitleDate of Registration
RecruitingISRCTN91737921
ODYSSEY: Once daily Dolutegravir in Young people vS Standard thErapY
08/08/2014
AuthorisedEUCTR2013-000087-29-IT
International study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2013-000087-29-SIInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.03/09/2013
AuthorisedEUCTR2013-000087-29-LVInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.02/09/2013
AuthorisedEUCTR2013-000087-29-GRInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.21/10/2013
AuthorisedEUCTR2013-000087-29-ESInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.12/07/2013
AuthorisedEUCTR2013-000087-29-DEInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.08/07/2013
AuthorisedEUCTR2013-000087-29-SEInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.29/10/2013
AuthorisedEUCTR2013-000087-29-BEInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.13/01/2014
AuthorisedEUCTR2013-000087-29-FIInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.30/07/2013
AuthorisedEUCTR2013-000087-29-LTInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.28/01/2014
AuthorisedEUCTR2013-000087-29-EEInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.10/10/2013
AuthorisedEUCTR2013-000087-29-PTInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.30/09/2013
AuthorisedEUCTR2013-000087-29-IEInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukaemia.12/09/2013
AuthorisedEUCTR2013-000087-29-PLInternational study evaluating safety of Obinutuzumab alone or in combination with chemotherapy in patients with Chronic Lymphocytic Leukemia.04/11/2013
RecruitingNCT01905943A Safety Study of Obinutuzumab Alone or in Combination With Chemotherapy in Patients With Chronic Lymphocytic Leukemia19/07/2013
02/07/2013
Not RecruitingEUCTR2012-003138-17-AT
A comparison of continuous Avastin treatment or placebo in addition to lomustine followed by standard treatment for worsening brain cancer
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2012-003138-17-GRClinical study evaluating if the patient is better and lives longer if bevacizumab is continued to be added to the standard treatment for worsening brain cancer25/06/2013
Not RecruitingEUCTR2012-003138-17-FIClinical study evaluating if the patient is better and lives longer if bevacizumab is continued to be added to the standard treatment for worsening brain cancer20/05/2013
AuthorisedEUCTR2012-003138-17-LVA comparison of continuous Avastin treatment or placebo in addition to lomustine followed by standard treatment for worsening brain cancer10/05/2013
AuthorisedEUCTR2012-003138-17-HRClinical study evaluating if the patient is better and lives longer if bevacizumab is continued to be added to the standard treatment for worsening brain cancer21/10/2014
Not RecruitingEUCTR2012-003138-17-ITClinical study evaluating if the patient is better and lives longer if bevacizumab is continued to be added to the standard treatment for worsening brain cancer03/05/2013
Not RecruitingEUCTR2012-003138-17-IEA comparison of continuous Avastin treatment or placebo in addition to lomustine followed by standard treatment for worsening brain cancer.03/05/2013
Not RecruitingEUCTR2012-003138-17-BGA comparison of continuous Avastin treatment or placebo in addition to lomustine followed by standard treatment for worsening brain cancer10/06/2013
Not RecruitingEUCTR2012-003138-17-LTA comparison of continuous Avastin treatment or placebo in addition to lomustine followed by standard treatment for worsening brain cancer26/04/2013
Not RecruitingEUCTR2012-003138-17-ESClinical study evaluating if the patient is better and lives longer if bevacizumab is continued to be added to the standard treatment for worsening brain cancer16/05/2013
Not RecruitingEUCTR2012-003138-17-PTA comparison of continuous Avastin treatment or placebo in addition to lomustine followed by standard treatment for worsening brain cancer04/06/2013
AuthorisedEUCTR2012-003138-17-SEClinical study evaluating if the patient is better and lives longer if bevacizumab is continued to be added to the standard treatment for worsening brain cancer30/05/2013
Not RecruitingEUCTR2012-003138-17-EEA comparison of continuous Avastin treatment or placebo in addition to lomustine followed by standard treatment for worsening brain cancer08/05/2013
AuthorisedEUCTR2012-003138-17-GBA comparison of continuous Avastin treatment or placebo in addition to lomustine followed by standard treatment for worsening brain cancer08/05/2013
RecruitingNCT01860638A Comparison of Continuous Avastin (Bevacizumab) Treatment or Placebo in Addition to Lomustine Followed by Standard of Care After Disease Progression in Patients With Glioblastoma21/05/2013
24/04/2013
AuthorisedEUCTR2012-000353-31-IT
Efficacy and safety study to compare deferiprone versus deferasirox in paediatric patients
Recruitment statusMain IDPublic titleDate of registration
Not AvailableEUCTR2012-000353-31-Outside-EU/EEAEfficacy and safety study to compare deferiprone versus deferasirox in paediatric patients10/04/2013
AuthorisedEUCTR2012-000353-31-GREfficacy and safety study to compare deferiprone versus deferasirox in paediatric patients14/04/2014
Not recruitingNCT01825512Efficacy/Safety Study of Deferiprone Compared to Deferasirox in Paediatric Patients03/04/2013
AuthorisedEUCTR2012-000353-31-GBEfficacy and safety study to compare deferiprone versus deferasirox in paediatric patients26/08/2014
11/10/2012
Not recruitingNCT01707992
The Efficacy and Safety and Tolerability of Laquinimod in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2012-003647-30-ESA clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).29/10/2012
AuthorisedEUCTR2012-003647-30-GRA clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).14/11/2012
AuthorisedEUCTR2012-003647-30-ITA multinational, multicenter, randomized, double-blind, parallel-group, placebo-controlled study followed by an active treatment period, to evaluate the efficacy, safety and tolerability of two doses of oral administration of laquinimod (0.6 mg/day or 1.2 mg/day) in subjects with relapsing remitting multiple sclerosis (RRMS)11/01/2013
AuthorisedEUCTR2012-003647-30-ATA clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).07/02/2013
AuthorisedEUCTR2012-003647-30-BEA clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).08/10/2012
AuthorisedEUCTR2012-003647-30-BGA clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).10/05/2013
AuthorisedEUCTR2012-003647-30-SKA clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).20/02/2014
AuthorisedEUCTR2012-003647-30-GBA clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).23/10/2012
AuthorisedEUCTR2012-003647-30-CZA clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).28/11/2012
AuthorisedEUCTR2012-003647-30-EEA clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).19/11/2012
AuthorisedEUCTR2012-003647-30-LVA clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).25/10/2012
AuthorisedEUCTR2012-003647-30-PLA clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).12/02/2013
AuthorisedEUCTR2012-003647-30-DEA clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).25/10/2012
AuthorisedEUCTR2012-003647-30-HUA clinical study in subjects with relapsing-remitting multiple sclerosis (RRMS) consisting of two parts: First part is to assess the efficacy, safety and tolerability of two oral doses of laquinimod either of 0.6 mg/day or 1.2mg/day (experimental drug) as compared placebo. Second part (all subjects receiving active treatment) is to evaluate the efficacy, safety and tolerability of two oral doses of laquinimod 0.6 mg/day or 1.2 mg/day (experimental drug).25/10/2012
28/09/2012
RecruitingNCT01663402
ODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab SAR236553 (REGN727)
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2011-005698-21-ESEvaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With SAR236553 (REGN727) (ODYSSEY Outcomes)29/11/2012
AuthorisedEUCTR2011-005698-21-ITEvaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment with SAR236553 (REGN/727) (ODYSSEY Outcomes)11/12/2012
AuthorisedEUCTR2011-005698-21-NOEvaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With SAR236553 (REGN727) (ODYSSEY Outcomes)13/11/2012
AuthorisedEUCTR2011-005698-21-SIODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab09/05/2014
AuthorisedEUCTR2011-005698-21-HRODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab03/09/2014
AuthorisedEUCTR2011-005698-21-LVODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab04/12/2012
AuthorisedEUCTR2011-005698-21-LTODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab21/11/2012
AuthorisedEUCTR2011-005698-21-FIODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab28/12/2012
AuthorisedEUCTR2011-005698-21-SEODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab01/11/2012
AuthorisedEUCTR2011-005698-21-GBODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab31/10/2012
AuthorisedEUCTR2011-005698-21-HUODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab23/11/2012
AuthorisedEUCTR2011-005698-21-GRODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab22/09/2014
AuthorisedEUCTR2011-005698-21-BGODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab27/12/2012
AuthorisedEUCTR2011-005698-21-BEODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab.07/11/2012
AuthorisedEUCTR2011-005698-21-NLODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab05/02/2013
AuthorisedEUCTR2011-005698-21-ATODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment Alirocumab09/01/2013
AuthorisedEUCTR2011-005698-21-PTODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab16/01/2013
AuthorisedEUCTR2011-005698-21-DEODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab10/12/2012
AuthorisedEUCTR2011-005698-21-EEODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab20/11/2012
AuthorisedEUCTR2011-005698-21-PLODYSSEY Outcomes: Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With Alirocumab25/02/2013
RecruitingCTRI/2014/02/004387Evaluation of Cardiovascular Outcomes After an Acute Coronary Syndrome During Treatment With SAR236553 (REGN727)07-02-2014
08/08/2012
RecruitingISRCTN11225767
Haemorrhage ALleviation with Tranexamic acid ? IntesTinal system
Recruitment statusMain IDPublic titleDate of registration
AuthorisedEUCTR2012-003192-19-GBTranexamic Acid for the treatment of significant gastrointestinal bleeding (bleeding from the gut) - HALT-IT15/02/2013
RecruitingNCT01658124Haemorrhage Alleviation With Tranexamic Acid- Intestinal System26/07/2012
03/07/2012
Not RecruitingCTRI/2012/05/002622
"Role of Tranexamic Acid (TXA) to reduce the bleeding in post delivery cases"
02-05-2012
Not RecruitingIRCT201012265467N1
The Impact of Omega-3 on Dry Eye
2012-04-03
Not RecruitingEUCTR2011-005550-57-LV
A clinical study in patients with multiple sclerosis to assess the efficacy, safety and tolerability of Glatiramer Acetate (GA) 20 mg/0.5 ml (experimental drug). 09/02/2012
    
1 2 3
Disclaimer: Trials posted on this search portal are not endorsed by WHO, but are provided as a service to our users. In no event shall the World Health Organization be liable for any damages arising from the use of the information linked to in this section. None of the information obtained through use of the search portal should in any way be used in clinical care without consulting a physician or licensed health professional. WHO is not responsible for the accuracy, completeness and/or use made of the content displayed for any trial record.
Copyright - World Health Organization - Version 3.2 - Version history